The Safety and Efficacy of Low-dose Tissue Plasminogen Activator in the Treatment of Systemic Sclerosis-Reference-Cited by-同舟云学术

The Safety and Efficacy of Low-dose Tissue Plasminogen Activator in the Treatment of Systemic Sclerosis

Published:1995-09 Issue:9 Volume:22 Page:637-642
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:The Journal of Dermatology

Author:

Wilson Diane¹,Edworthy Steven M.¹,Hart David A.¹,Fritzler Marvin J.¹

Affiliation:

1. Joint Injury and Arthritis Research Group; The University of Calgary; 3330 Hospital Drive N.W. Calgary Alberta Canada T2N 4N1

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1346-8138.1995.tb03890.x/fullpdf

Reference17 articles.

1. Cutaneous fibrinolytic activity in scleroderma;Lotti;Clin Exper Rheumatol,1985

2. Regulation of plasminogen activators and their inhibitors in rheumatic disease: New understanding and the potential for new directions;Hart;J Rheumatol,1989

3. Sequential dermal microvascular changes in the development of scleroderma;Prescott;J Pathol,1992

4. Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy;Fritzler;Arthritis Rheum,1990

5. Progressive systemic sclerosis;Steen;Ann Int Med,1982

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of rituximab in the treatment of systemic sclerosis: A literature review;Modern Rheumatology;2023-04-13

2. Assessment of skin involvement in systemic sclerosis;Rheumatology;2017-09-01

3. SCLERODERMA 710.1 (Systemic Sclerosis, Progressive Systemic Sclerosis);Roy and Fraunfelder's Current Ocular Therapy;2008

4. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis;Seminars in Arthritis and Rheumatism;2003-04

5. Treatment with Interferon Gamma Enhances Fibrinolysis in Systemic Sclerosis;Thrombosis Research;1998-08